Last 12 months
Inside the activity.
0 purchase rows · 169 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 23 |
| Dec 2025 | 0 | 18 |
| Jan 2026 | 0 | 44 |
| Feb 2026 | 0 | 22 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 10 |
| May 2026 | 0 | 19 |
| Jun 2026 | 0 | 13 |
| Jul 2026 | 0 | 7 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 20:04 UTC |
Brennan David RDirector
|
SaleCommon Stock | 25,000 | $124.00 | $3,100,000.00 |
DisclosureSEC source: 0001609305-26-000009 · wk-form4_1789157083.xml · nonDerivative · entry 1 Brennan David R · CIK 0001609305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,238 Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC |
SHAROKY MELVIN MDDirector
|
SaleCommon Stock | 5,000 | $127.53 | $637,650.00 |
DisclosureSEC source: 0001182633-26-000010 · wk-form4_1787170216.xml · nonDerivative · entry 1 SHAROKY MELVIN MD · CIK 0001182633 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Padonia, LLC Disclosed balance after: 0 F1 · price: This is the weighted average sales price representing 5,000 shares sold at prices ranging from $127.51 to $127.61 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · ownership.nature: The Reporting Person is the managing member of Padonia, LLC. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:04 UTC |
Adsett RogerChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 80,970 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · derivative · entry 7 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,970 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:04 UTC |
Adsett RogerChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 76,600 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · derivative · entry 6 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,600 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:04 UTC |
Adsett RogerChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 82,280 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · derivative · entry 5 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,280 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:04 UTC |
Adsett RogerChief Operating Officer
|
SaleCommon Stock | 239,850 | $133.27 | $31,964,809.50 |
DisclosureSEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 4 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,744 F2 · price: This is the weighted average sales price representing 239,850 shares sold at prices ranging from $133.00 to $133.51 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:04 UTC |
Adsett RogerChief Operating Officer
|
Exercise / conversionCommon Stock | 80,970 | $30.46 | $2,466,346.20 |
DisclosureSEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:04 UTC |
Adsett RogerChief Operating Officer
|
Exercise / conversionCommon Stock | 76,600 | $17.16 | $1,314,456.00 |
DisclosureSEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:04 UTC |
Adsett RogerChief Operating Officer
|
Exercise / conversionCommon Stock | 82,280 | $13.67 | $1,124,767.60 |
DisclosureSEC source: 0001685904-26-000014 · wk-form4_1786568667.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:39 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,895 | $0.00 Strike: $25.83 | $0.00 |
DisclosureSEC source: 0001796960-26-000020 · wk-form4_1786135147.xml · derivative · entry 6 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,580 Underlying: Common Stock · 8,895 shares Expires 2034-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the Initial Vesting Date. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:39 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,278 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0001796960-26-000020 · wk-form4_1786135147.xml · derivative · entry 5 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,555 Underlying: Common Stock · 18,278 shares Expires 2033-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:39 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 18,278 | $129.40 | $2,365,173.20 |
DisclosureSEC source: 0001796960-26-000020 · wk-form4_1786135147.xml · nonDerivative · entry 4 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,486 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 18,278 shares sold at prices ranging from $129.40 to $129.41 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:39 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 8,895 | $127.00 | $1,129,665.00 |
DisclosureSEC source: 0001796960-26-000020 · wk-form4_1786135147.xml · nonDerivative · entry 3 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,764 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:39 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 8,895 | $25.83 | $229,757.85 |
DisclosureSEC source: 0001796960-26-000020 · wk-form4_1786135147.xml · nonDerivative · entry 2 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:39 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 18,278 | $18.95 | $346,368.10 |
DisclosureSEC source: 0001796960-26-000020 · wk-form4_1786135147.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000042 · wk-form4_1784926946.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,260 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000042 · wk-form4_1784926946.xml · derivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,260 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 5,872 | $106.43 | $624,956.96 |
DisclosureSEC source: 0001402051-26-000042 · wk-form4_1784926946.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,058 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 4,828 | $105.62 | $509,933.36 |
DisclosureSEC source: 0001402051-26-000042 · wk-form4_1784926946.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,930 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000042 · wk-form4_1784926946.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 23, 2026 Filed Jul 24, 2026 21:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 6,260 | $30.46 | $190,679.60 |
DisclosureSEC source: 0001402051-26-000042 · wk-form4_1784926946.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000040 · wk-form4_1783713769.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,440 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000040 · wk-form4_1783713769.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,260 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 3,359 | $118.52 | $398,108.68 |
DisclosureSEC source: 0001402051-26-000040 · wk-form4_1783713769.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 259,058 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 3,359 shares sold at prices ranging from $118.06 to $118.80 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 2,335 | $117.62 | $274,642.70 |
DisclosureSEC source: 0001402051-26-000040 · wk-form4_1783713769.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,417 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 2,335 shares sold at prices ranging from $117.05 to $117.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 5,005 | $116.55 | $583,332.75 |
DisclosureSEC source: 0001402051-26-000040 · wk-form4_1783713769.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,752 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 5,005 shares sold at prices ranging from $116.01 to $117.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000040 · wk-form4_1783713769.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 20:02 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000040 · wk-form4_1783713769.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 141 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:03 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,357 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0001796960-26-000018 · wk-form4_1783541018.xml · derivative · entry 6 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,358 Underlying: Common Stock · 4,357 shares Expires 2033-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:03 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,945 | $0.00 Strike: $29.13 | $0.00 |
DisclosureSEC source: 0001796960-26-000018 · wk-form4_1783541018.xml · derivative · entry 5 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,835 Underlying: Common Stock · 7,945 shares Expires 2034-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:03 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 7,448 | $110.60 | $823,748.80 |
DisclosureSEC source: 0001796960-26-000018 · wk-form4_1783541018.xml · nonDerivative · entry 4 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,486 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 7,448 shares sold at prices ranging from $110.36 to $110.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:03 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 4,854 | $109.02 | $529,183.08 |
DisclosureSEC source: 0001796960-26-000018 · wk-form4_1783541018.xml · nonDerivative · entry 3 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,934 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 4,854 shares sold at prices ranging from $108.90 to $109.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:03 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 4,357 | $19.74 | $86,007.18 |
DisclosureSEC source: 0001796960-26-000018 · wk-form4_1783541018.xml · nonDerivative · entry 2 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:03 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 7,945 | $29.13 | $231,437.85 |
DisclosureSEC source: 0001796960-26-000018 · wk-form4_1783541018.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,880 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,880 Underlying: Common Stock · 8,880 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 12,518 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,519 Underlying: Common Stock · 12,518 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 1,292 | $106.27 | $137,300.84 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,917 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 1,292 shares sold at prices ranging from $105.90 to $106.45 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 2,456 | $105.27 | $258,543.12 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,209 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,456 shares sold at prices ranging from $104.90 to $105.88 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 3,723 | $104.28 | $388,234.44 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,665 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 3,723 shares sold at prices ranging from $103.87 to $104.75 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 1,836 | $103.10 | $189,291.60 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,388 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,836 shares sold at prices ranging from $102.78 to $103.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 12,091 | $102.34 | $1,237,392.94 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,224 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 12,091 shares sold at prices ranging from $101.78 to $102.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 8,880 | $17.16 | $152,380.80 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:03 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 12,518 | $30.46 | $381,298.28 |
DisclosureSEC source: 0001402051-26-000038 · wk-form4_1782504217.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:15 UTC |
Butera SamueleSVP, GM, Global Respiratory
|
GrantStock Option (right to buy) · Derivative | 12,570 | $0.00 Strike: $102.15 | $0.00 |
DisclosureSEC source: 0002140098-26-000005 · wk-form4_1782332113.xml · derivative · entry 2 Butera Samuele · CIK 0002140098 · SVP, GM, Global Respiratory 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,570 Underlying: Common Stock · 12,570 shares Expires 2036-06-23 F3 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:15 UTC |
Butera SamueleSVP, GM, Global Respiratory
|
GrantCommon Stock | 7,342 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002140098-26-000005 · wk-form4_1782332113.xml · nonDerivative · entry 1 Butera Samuele · CIK 0002140098 · SVP, GM, Global Respiratory 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,342 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on June 23, 2026, for no consideration. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:11 UTC |
Smith Michael AlexanderChief Legal Officer
|
SaleCommon Stock | 1,806 | $95.82 | $173,050.92 |
DisclosureSEC source: 0001870278-26-000020 · wk-form4_1782331897.xml · nonDerivative · entry 1 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,648 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:05 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 6,515 | $94.03 | $612,605.45 |
DisclosureSEC source: 0001402051-26-000035 · wk-form4_1781121933.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 258,917 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 20:11 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 1,858 | $103.78 | $192,823.24 |
DisclosureSEC source: 0001796960-26-000016 · wk-form4_1780690310.xml · nonDerivative · entry 2 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,486 F2 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:15 UTC |
Adsett RogerChief Operating Officer
|
SaleCommon Stock | 2,370 | $102.27 | $242,379.90 |
DisclosureSEC source: 0001685904-26-000012 · wk-form4_1780690556.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,603 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:14 UTC |
Bonstein SaraChief Financial Officer
|
SaleCommon Stock | 2,404 | $102.27 | $245,857.08 |
DisclosureSEC source: 0001604019-26-000010 · wk-form4_1780690483.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,082 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.